

Review Form 3

Journal Name:	International Research Journal of Oncology
Manuscript Number:	Ms_IRJO_123000
Title of the Manuscript:	Breaking Barriers in Non Small Cell Lung Cancer Treatment: Ceritinib's Role in Advancing Targeted Therapy
Type of the Article	Systemic review

Review Form 3

PART 1: Review Comments

Compulsory REVISION comments	Reviewer's comment	Author's Feedback <i>(Please correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)</i>
Please write a few sentences regarding the importance of this manuscript for the scientific community. Why do you like (or dislike) this manuscript? A minimum of 3-4 sentences may be required for this part.	The manuscript provides a review of Ceritinib's role in NSCLC treatment, covering its mechanism, efficacy, safety, and potential in combination therapies. It brings together findings from multiple clinical trials, offering a consolidated view of Ceritinib's therapeutic landscape.	
Is the title of the article suitable? (If not please suggest an alternative title)	yes	
Is the abstract of the article comprehensive? Do you suggest the addition (or deletion) of some points in this section? Please write your suggestions here.	yes	
Are subsections and structure of the manuscript appropriate?	<p>The existing subsections within the manuscript are appropriate; however, to enhance the comprehensiveness and depth of the analysis, it is essential to incorporate additional information into the existing sections and to introduce new subsections</p> <p>Sub-sections must be added</p> <ol style="list-style-type: none"> 1. The mechanism Ceritinib exhibits to overcome resistance commonly observed with other ALK inhibitors. 2. Ceritinib resistance and methods to overcome Ceritinib resistance 3. compare Crizotinib with other first line ALK inhibitors in different points of efficiency(ORR, PFS , DoR) <p>Information to be added in already existing sections</p> <ol style="list-style-type: none"> 1. Clinical sufficiency and safety profile section need to add comparative studies between Ceritinib and other ALK inhibitor focuses on safety profile and adverse drug reactions as no any study is written in this section 2. The section on dosing and administration should include a detailed examination of the pharmacokinetic interactions of Crizotinib with other medications. Specifically, it is crucial to address how Crizotinib's metabolism and efficacy may be altered by concomitant use of other drugs, including those that affect CYP3A4 enzyme activity, as Crizotinib is a known substrate of this enzyme. Additionally, potential interactions with drugs that impact drug transporters, such as P-glycoprotein, should be considered to fully understand the implications for treatment management and patient safety. 3. The section on combination therapy should be expanded to include a comprehensive review of Crizotinib in conjunction with various therapeutic agents. This review should cover not only established combinations with other targeted therapies and chemotherapy agents but also investigate emerging data from preclinical studies. In the absence of extensive clinical trials, the manuscript should discuss the findings from animal studies that evaluate the efficacy and safety of Crizotinib in combination with these agents, providing insights into potential synergistic effects and interactions. This addition will support his conclusion 	
Please write a few sentences regarding the scientific correctness of this manuscript. Why do you think that this manuscript is scientifically robust and technically sound? A minimum of 3-4 sentences may be required for this part.	This manuscript is scientifically robust and technically sound due to its thorough exploration of Ceritinib's role in treating ALK-positive non-small cell lung cancer (NSCLC). It is grounded in current scientific knowledge, highlighting both preclinical models and clinical trials that demonstrate Ceritinib's efficacy and safety. The manuscript systematically reviews key aspects such as the drug's mechanism of action, clinical efficacy in treatment-naïve and resistant	

Review Form 3

	patients, and management of side effects. It also integrates recent advancements in targeted therapy and combination strategies, underscoring its relevance and applicability in the evolving landscape of NSCLC treatment	
Are the references sufficient and recent? If you have suggestions of additional references, please mention them in the review form.	yes	
<u>Minor</u> REVISION comments Is the language/English quality of the article suitable for scholarly communications?	yes	
<u>Optional/General</u> comments		

PART 2:

	Reviewer's comment	Author's comment (if agreed with the reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Are there ethical issues in this manuscript?	NO	

Reviewer Details:

Name:	Mostafa Wael
Department, University & Country	Modern University for Technology and Information, Egypt